This COVID-19 Shot Stock Could Have Eye Disease Gene Therapy As Significant Driver, Mizuho Analyst Says

• Mizuho initiated coverage on Ocugen Inc (NASDAQ: OCGN) with a Buy rating and a price target of $5, reflecting an upside of almost 115%.

• Mizuho views Ocugen as a high-risk, high-reward opportunity.

• While the lead asset, a COVID-19 vaccine (Covaxin), offers potential near-term cash flow to help offset operational costs, Mizuho believes OCU400, a Phase 1/2 gene therapy for eye disease, is a more significant value driver for the company.

• According to the analyst, the current stock price primarily reflects the value of Covaxin.

• Related: Ocugen's Partner COVID-19 Vaccine Covaxin Shows Encouraging Action In Children Below 18 Years.

• "If approved, we believe COVAXIN could be attractive to individuals in the US seeking a broad antibody response against multiple antigens or waiting for a traditionally made COVID-19 vaccine due to their discomfort with mRNA vaccines," Mizuho writes.

• The stock price incorporates little to no value for OCU400, setting up a favorable risk/reward going into the first human efficacy data readout for OCU400 in 1H23.

• The analyst models a 20% probability of success sales of $455 million ($2.3 billion unadjusted) in 2030 for five key inherited retinal diseases (with cumulative sales of $3.3 billion ($16.3 billion unadjusted) for 2026-2035E).

• Price Action: OCGN shares are up 3.85% at $2.43 during the premarket session on the last check Tuesday.

Latest Ratings for OCGN

Date	Firm	Action	From	To
Feb 2022	HC Wainwright & Co.	Maintains		Buy
Jun 2021	Roth Capital	Downgrades	Buy	Neutral
Jun 2021	HC Wainwright & Co.	Maintains		Buy

View More Analyst Ratings for OCGN

View the Latest Analyst Ratings

See more from Benzinga

• Medtronic Q1 Earnings Within Expectation, Sees Higher Currency Headwind On FY23 Sales

• Owl Creek Urges Cano Health Board To Consider Potential Sale

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.